Insurance for Indian Healthtech and Telemedicine Platforms: Professional Liability, Data Breach, and Regulatory Exposure

India's digital health market crossed INR 53,000 crore in 2025, propelled by a post-pandemic surge in teleconsultation volumes, the rollout of the Ayushman Bharat Digital Mission (ABDM), and a steady stream of venture capital. Platforms such as Practo, Tata Health, MFine, and dozens of smaller startups now handle everything from video consultations and e-prescriptions to AI-driven symptom checkers and remote patient monitoring. That breadth of activity, however, creates a correspondingly wide risk surface.

Unlike a pure-play SaaS company whose worst-case scenario is typically service downtime, a healthtech platform sits at the intersection of regulated medical practice, sensitive personal data, and consumer safety. A misdiagnosis during a teleconsultation can result in bodily harm. A data breach exposing patient health records attracts penalties under the Digital Personal Data Protection (DPDP) Act, 2023, and reputational damage that can be terminal for a health brand. A connected medical device that malfunctions triggers product liability claims. Each of these risk categories requires a distinct insurance response.

The regulatory overlay adds another dimension. The Telemedicine Practice Guidelines 2020, issued by the Board of Governors of the Medical Council of India, impose specific duties on registered medical practitioners conducting teleconsultations, but the platforms that enable those consultations occupy an ambiguous zone. IRDAI has not yet issued sector-specific guidance for healthtech, which means standard policy wordings often do not account for telehealth-specific exposures. Founders frequently discover this only at the point of claim, when an insurer declines cover on the basis that the activity falls outside the policy's professional services definition.

This article maps the full insurance stack that an Indian healthtech company should evaluate, from professional indemnity and cyber liability to product liability for connected devices and directors and officers cover for regulatory investigations. For each line of cover, we flag the policy wording traps that are specific to digital health and suggest practical steps to close gaps before a loss event forces the conversation.

Professional indemnity insurance is the first line of defence for any healthtech platform that facilitates clinical decisions. When a patient alleges that a teleconsultation led to a wrong diagnosis, a delayed referral, or an inappropriate prescription, the resulting claim can name both the treating doctor and the platform that matched the patient with that doctor. Indian courts have increasingly treated platforms as having a duty of care when they vet, list, or algorithmically assign healthcare providers.

A standard professional indemnity policy for IT companies will typically define covered services as technology consulting, software development, or data processing. Teleconsultation facilitation, clinical triage, or AI-assisted diagnosis rarely appears in these definitions. Healthtech companies must negotiate bespoke professional services descriptions that capture the full range of activities, including symptom-checker algorithms that recommend urgency levels, e-pharmacy modules that suggest drug interactions, and remote monitoring dashboards that alert clinicians to vital-sign anomalies.

Pricing for such cover in the Indian market currently sits between INR 1.5 lakh and INR 8 lakh per annum for limits of INR 1 crore to INR 5 crore, depending on the platform's consultation volumes, the medical specialities offered, and whether the platform employs doctors directly or operates a marketplace model. Marketplace models tend to attract lower premiums because the platform can argue that clinical judgment rests with the independent practitioner, but this argument weakens if the platform's algorithm overrides or constrains the practitioner's choices.

Retroactive date provisions matter greatly in this sector. Many healthtech companies pivot rapidly, adding new clinical modules every quarter. If the policy's retroactive date is set to the inception date rather than the date the company first began offering clinical services, claims arising from earlier activities will be excluded. Founders should insist on a retroactive date that matches the company's first day of clinical operations and should maintain continuous cover without gaps, because professional indemnity policies are written on a claims-made basis and any break in cover can leave the company exposed to tail claims from prior periods.

It is also worth checking whether the policy covers disciplinary proceedings. Under the Telemedicine Practice Guidelines, the Board of Governors can initiate proceedings against a registered medical practitioner, and the platform's in-house medical director may be caught in such actions. Defence costs for regulatory proceedings can be substantial and should be covered under the policy.

Health data is classified as sensitive personal data under India's Information Technology (Reasonable Security Practices and Procedures and Sensitive Personal Data or Information) Rules, 2011, and the DPDP Act, 2023 further tightens obligations around consent, purpose limitation, and breach notification. For a healthtech platform, a single data breach can expose patient diagnoses, prescription histories, and biometric data, triggering regulatory penalties, class action litigation, and a collapse in user trust.

Cyber insurance for healthtech must go beyond the generic first-party/third-party structure that suffices for a typical SaaS company. First-party covers should include forensic investigation costs, breach notification expenses (the DPDP Act requires notification to the Data Protection Board of India within a prescribed timeline), credit monitoring services for affected patients, and business interruption losses arising from a mandated system shutdown. Third-party covers should address regulatory defence costs, fines and penalties to the extent insurable under Indian law, and liability to affected data principals who bring claims for compensation.

A critical policy wording issue for healthtech companies is the definition of a privacy event or data breach. Some wordings require unauthorised external access, which would exclude incidents such as an internal employee viewing patient records without authorisation, a misconfigured API that inadvertently exposes data, or a third-party lab integration that leaks results. The policy should define a breach broadly to include any unauthorised access, acquisition, disclosure, or use of protected health information, regardless of whether the cause is external hacking or internal process failure.

Limits of indemnity for cyber cover in the Indian healthtech space typically range from INR 50 lakh to INR 10 crore. Companies processing more than 10 lakh patient records annually should consider limits at the higher end, because the per-record cost of a health data breach (including forensics, notification, and potential DPDP Act penalties of up to INR 250 crore for significant data fiduciaries) can escalate quickly. Deductibles in this segment usually range from INR 2 lakh to INR 10 lakh.

Healthtech companies should also verify whether their cyber policy covers claims arising from AI-driven data processing. If a machine learning model inadvertently uses patient data for a purpose outside the stated consent, or if the model's training data set is compromised, the resulting liability may fall outside a narrowly worded cyber policy. Specific AI liability endorsements are beginning to appear in the Indian market and should be actively sought.

India's healthtech ecosystem increasingly extends beyond software into hardware: wearable ECG monitors, connected glucometers, pulse oximeters sold under private labels, and AI-powered imaging analysis tools. Each of these products carries a liability profile that is distinct from the platform's software services, and each requires a separate insurance response.

Product liability insurance covers claims arising from bodily injury or property damage caused by a defective product. Under the Consumer Protection Act, 2019, a product liability action can be brought against the manufacturer, the product seller, or the product service provider. A healthtech company that designs a wearable device and contracts manufacturing to a third-party OEM in Shenzhen or Noida can still be held liable as the product seller or as the entity whose brand appears on the device. If the device's software, rather than its hardware, causes the defect (for example, an algorithm that misreads a heart rhythm), the claim can also be framed as a deficiency in service, pulling the platform back into professional indemnity territory.

The interplay between product liability and professional indemnity is a recurring coverage gap for healthtech companies. A standard product liability policy will exclude professional advice or services, while a professional indemnity policy will exclude bodily injury arising from a tangible product. If a patient suffers harm because a connected blood pressure monitor gave a false normal reading and the platform's triage algorithm consequently failed to recommend emergency care, both policies may point to each other's exclusion. The solution is to ensure that the professional indemnity policy includes a carve-back for claims arising from the use of technology-enabled medical devices in the delivery of covered professional services, and that the product liability policy does not exclude software-related defects.

Pricing for product liability cover depends on the device's risk classification under the Medical Devices Rules, 2017 (administered by CDSCO). Class A devices such as simple thermometers attract lower premiums than Class C or Class D devices such as cardiac monitors. Annual premiums for a healthtech company with product liability exposure typically range from INR 3 lakh to INR 15 lakh for limits of INR 2 crore to INR 10 crore.

Companies developing AI-based diagnostic tools should also consider clinical trial liability cover if they are conducting validation studies. ICMR guidelines require ethics committee approval for clinical research, and any adverse event during a trial can generate claims that standard product liability or professional indemnity policies may not address.

The Telemedicine Practice Guidelines 2020 established a framework for teleconsultation in India, specifying which conditions can be managed remotely, what prescribing restrictions apply (Schedule X drugs, for instance, cannot be prescribed via teleconsultation), and what records must be maintained. While these guidelines primarily bind registered medical practitioners rather than platforms, regulatory enforcement actions against platforms have been increasing, particularly when platforms are found to be facilitating consultations that fall outside the guidelines' scope.

Directors and officers (D&O) liability insurance becomes relevant here. If IRDAI, the Drug Controller General of India, or a state medical council initiates an investigation or enforcement action against the platform's directors, the defence costs can be significant even if no fine is ultimately imposed. A D&O policy with a regulatory investigation extension covers the costs of responding to formal investigations, producing documents, and engaging legal counsel. The policy should not be limited to securities-related claims, which is a common restriction in policies designed for listed companies. Healthtech startups need a D&O policy that covers regulatory proceedings by any governmental or quasi-governmental body.

The Digital Health Regulatory Framework, expected to be tabled before Parliament, will likely impose licensing requirements on digital health platforms, mandate interoperability with the ABDM ecosystem, and create a dedicated regulator or expand IRDAI's remit to cover health data intermediaries. Companies that are building their technology stack today should anticipate these requirements and ensure their insurance programme can adapt. A management liability policy with a broad definition of regulatory proceedings, rather than one tied to specific statutes, provides the necessary flexibility.

Another underappreciated exposure is the liability arising from non-compliance with the Drugs and Cosmetics Act, 1940. Healthtech platforms that operate e-pharmacy modules must hold or partner with entities that hold valid drug licences. If a prescription drug is dispensed without a valid prescription, or if a controlled substance is shipped to a jurisdiction where the platform's licence is not valid, the resulting regulatory action can lead to criminal prosecution of the directors. While insurance cannot cover criminal fines, it can cover the defence costs associated with such proceedings, and this cover is usually provided under the D&O policy's defence costs component.

Platforms should also monitor the National Medical Commission's ongoing review of telehealth standards, as any tightening of the rules around AI-assisted triage or automated prescribing could expand the liability surface overnight.

A well-structured insurance programme for an Indian healthtech company should include at least five lines of cover: professional indemnity, cyber liability, product liability (if devices or AI diagnostics are involved), D&O liability, and commercial general liability (CGL). The challenge lies not just in procuring these covers individually but in ensuring they interact correctly so that no claim falls into a gap between two policies.

The first step is to appoint a single broker or insurance advisor who understands the healthtech vertical and can coordinate the placement of all lines. Indian insurers such as ICICI Lombard, HDFC Ergo, Bajaj Allianz, and New India Assurance offer professional indemnity and cyber products, but the wordings vary significantly. A broker who has placed similar programmes for health platforms can identify which insurer's wording is most accommodating for telehealth-specific risks and can negotiate endorsements where the standard wording falls short.

Layering is particularly relevant for companies with higher risk profiles. Rather than purchasing a single INR 25 crore professional indemnity policy from one insurer, a company might buy a primary layer of INR 5 crore from one insurer and an excess layer of INR 20 crore from another. This approach distributes risk across multiple balance sheets and can sometimes reduce the overall premium cost because excess layers are priced at lower rates per crore of cover.

Cross-liability clauses should be checked in the CGL policy. If a patient visits a co-located clinic that the platform operates and suffers a slip-and-fall injury, the CGL policy covers the bodily injury claim. But if the patient also alleges that the fall was caused by negligent advice to visit the clinic (for example, the platform's algorithm recommended an in-person visit that was unnecessary), the professional indemnity policy may also be triggered. The policies should contain non-contribution or cooperation clauses that prevent both insurers from declining cover by pointing to the other policy.

Premium budgets for early-stage healthtech companies (pre-Series A) typically range from INR 5 lakh to INR 15 lakh per annum for a basic programme covering professional indemnity, cyber, and D&O. Post-Series B companies with significant patient volumes and device portfolios may spend INR 30 lakh to INR 1 crore annually. These figures are rough benchmarks. Actual pricing depends on claims history, the company's security posture (SOC 2 and ISO 27001 certifications can reduce cyber premiums by 10-15%), and the specific activities covered.

Renewal management is critical. Healthtech companies evolve rapidly, adding new clinical modules, entering new geographies, or integrating new device partners every quarter. Each material change should be disclosed to the insurer mid-term, ideally via an endorsement, to avoid a claim being declined on the basis that the activity was not disclosed at inception.

Examining real-world and hypothetical claims scenarios helps illustrate where coverage gaps tend to appear. While Indian healthtech litigation is still in its early stages compared to the US, several cases and regulatory actions provide useful signals.

In 2023, the National Consumer Disputes Redressal Commission (NCDRC) heard a matter involving a patient who alleged that a teleconsultation platform's triage algorithm incorrectly classified chest pain as gastric distress, leading to a delayed cardiac intervention. The platform argued that the algorithm only provided preliminary guidance and that the treating doctor made the clinical decision. The Commission held that the platform bore partial responsibility because its user interface presented the algorithm's output in a manner that could reasonably influence the doctor's assessment. The platform's professional indemnity insurer initially resisted the claim on the ground that algorithmic output is a technology service, not a professional service. Settlement was eventually reached, but the dispute highlights the need for a professional indemnity wording that explicitly includes AI and algorithm-assisted clinical decision support.

Data breach incidents have also surfaced. A mid-size healthtech company in Bengaluru discovered in 2024 that a third-party diagnostic lab integration had been leaking patient reports via an unsecured API endpoint for over six months. Approximately 2.3 lakh patient records were exposed, including HIV test results. The company's cyber policy responded for forensic investigation and notification costs but excluded the subsequent regulatory penalty imposed by the IT Ministry under the SPDI Rules, because the policy defined covered penalties as those arising from a data breach event, and the regulator characterised the exposure as a systemic compliance failure rather than a breach event. This illustrates the importance of a broad trigger definition in the cyber policy.

On the product liability front, a connected pulse oximeter sold by a healthtech startup was found to give readings with a 4% variance from clinical-grade devices. While this is within the range disclosed in the device's documentation, several users relied on the readings to avoid hospital visits during a COVID wave, resulting in delayed treatment. The product liability claim was complicated by the fact that the variance was disclosed, but the platform's marketing materials featured testimonials suggesting the device was as accurate as hospital equipment. Misleading advertising can vitiate a product liability defence, and the advertising injury cover under a CGL policy became relevant.

These scenarios underscore a consistent theme: healthtech claims rarely fit neatly into a single policy's coverage. A coordinated programme with clear inter-policy referencing, combined with proactive disclosure of all activities to insurers, is the best defence against coverage disputes at the point of claim.

Given the complexity of the risk profile, healthtech founders should treat insurance procurement as a board-level priority rather than a compliance afterthought. The following checklist summarises the key actions discussed in this article.

First, map every clinical and non-clinical activity the platform performs. This includes teleconsultation facilitation, e-prescriptions, AI-driven triage, remote monitoring, device sales, e-pharmacy operations, and health data analytics. Each activity generates a distinct liability and requires coverage under a specific policy line. A coverage map, ideally prepared in collaboration with a broker, ensures that no activity is left uninsured.

Second, review professional indemnity policy wordings for telehealth-specific definitions. The covered professional services definition must include algorithm-assisted clinical decision support, teleconsultation facilitation, and any activity that could be characterised as the practice of medicine under the Indian Medical Council Act or the National Medical Commission Act, 2019.

Third, procure cyber insurance with a breach definition that covers internal and external incidents, API vulnerabilities, and AI-related data misuse. Verify that the policy covers DPDP Act penalties and defence costs for Data Protection Board proceedings. If the company processes data of EU residents (common for platforms with NRI user bases), ensure the policy also addresses GDPR exposure.

Fourth, evaluate product liability cover if the company sells, brands, or distributes any physical device or AI diagnostic tool. Check for the software-exclusion gap between product liability and professional indemnity policies and close it through endorsements.

Fifth, secure D&O cover with a regulatory investigation extension that is not limited to securities regulators. Healthtech directors face exposure from the Drug Controller, state medical councils, the Data Protection Board, and potentially a future digital health regulator.

Sixth, build a renewal discipline. Disclose every new activity, partnership, geographic expansion, and technology change to insurers at renewal and, if material, mid-term via endorsement. Failure to disclose can give insurers grounds to deny claims.

Seventh, maintain claims records meticulously. Professional indemnity and D&O policies are claims-made, meaning the claim must be reported within the policy period. A 30-day late notification can be fatal to coverage. Implement an internal protocol that routes any complaint, legal notice, or regulatory inquiry to the insurance team within 48 hours.

By treating insurance as a strategic function rather than an annual procurement exercise, healthtech founders can protect their companies against the sector's distinctive and growing risks while also strengthening their position in investor due diligence and enterprise sales.